ESGCT session on in vivo gene editing in preclinical model delivers new data from both Prime Medicine and Tessera ...

H.C. Wainwright analyst Arthur He CFA maintained a Buy rating on Prime Medicine, Inc. (PRME – Research Report) today and set a price ...

In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Prime Medicine, Inc. (PRME – Research Report), with a ...

A feud between Prime Medicine and Tessera Therapeutics, two gene-editing companies, has spilled out into public.

On Monday, Prime Medicine Inc (PRME) stock saw a modest uptick, ending the day at $4.21 which represents a slight increase of $0.18 or 4.47% from the prior close of $4.03. The stock opened at $4.12 ...

On Friday, Prime Medicine Inc (PRME) stock saw a decline, ending the day at $4.03 which represents a decrease of $-0.17 or -4.05% from the prior close of $4.2. The stock opened at $4.18 and touched a ...

CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic ...

A fierce rivalry is brewing between gene-editing companies Prime Medicine and Tessera Therapeutics. Jeremy Duffield, Prime’s ...

Oct. 15, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies ...

Millennium Management LLC increased its holdings in Prime Medicine, Inc. (NYSE:PRME – Free Report) by 205.7% during the 2nd quarter, Holdings Channel reports.The firm owned 1,330,927 shares of ...

New research demonstrates the potential of precise genome editing technologies, called adenine base editors, to correct disease-causing mutations in stem cells from patients with X-linked chronic ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.